Loading…
Immutep Limited is projected to rise to $0.4912 by 2027, a +29% move from its current price of $0.3804. IMMP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.3706 | $0.3808 | $0.3913 | +0.11% |
| Aug 6 | $0.3669 | $0.3812 | $0.3962 | +0.22% |
| Aug 7 | $0.3641 | $0.3817 | $0.4001 | +0.33% |
| Aug 8 | $0.3619 | $0.3821 | $0.4035 | +0.44% |
| Aug 9 | $0.3599 | $0.3825 | $0.4065 | +0.56% |
| Aug 10 | $0.3583 | $0.3829 | $0.4093 | +0.67% |
| Aug 11 | $0.3567 | $0.3834 | $0.412 | +0.78% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3567 | $0.3834 | $0.412 | +0.78% |
| Week 2 | $0.349 | $0.3863 | $0.4277 | +1.56% |
| Week 3 | $0.3437 | $0.3894 | $0.441 | +2.35% |
| Week 4 | $0.3398 | $0.3924 | $0.4531 | +3.15% |
| Week 5 | $0.3367 | $0.3954 | $0.4645 | +3.95% |
| Week 6 | $0.3341 | $0.3985 | $0.4753 | +4.76% |
| Week 7 | $0.332 | $0.4016 | $0.4859 | +5.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immutep Limited is a biotechnology company that develops novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
The company’s product pipeline includes TACTI-004 in phase III for first line non-small cell lung cancer (1L NSCLC); TACTI-003 in phase IIb to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 in phase I for metastatic urothelial carcinoma; TACTI-002 in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003 in phase II/III to treat metastatic breast cancer; and EFTISARC-NEO in phase II for soft tissue sarcoma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited (IMMP) is a biotechnology company with a current price of $0.3808 and a market capitalization of $56.12M. It holds the 4491st rank by market cap among listed assets. The stock is positioned within a path of gradual, long-term upside in its forecast, with a neutral stance expected in 2026 and bullish implications emerging in subsequent years.
Forecasts indicate a rising average price from 2026 onward, with a max outlook reaching $3.34 by 2050 and a 363.9% potential max ROI in that year range. The data imply meaningful upside over the multi-year horizon, albeit within a framework of inherent investment risk and uncertainty.
A major floor 18.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 18.3% above — a clean break opens room to run.
A major ceiling 63.0% above — clearing it would confirm fresh momentum.
Key IMMP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMMP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.382 | Sell | $0.3828 | Sell |
| MA 10 | $0.388 | Sell | $0.39 | Sell |
| MA 20 | $0.4105 | Sell | $0.399 | Sell |
| MA 50 | $0.4068 | Sell | $0.4578 | Sell |
| MA 100 | $0.4938 | Sell | $0.722 | Sell |
| MA 200 | $1.48 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.03 | Neutral |
| Stoch RSI (14) | 7.57 | Buy |
| CCI (20) | -90.17 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -13.64 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 31.39 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.38 | Buy |
| ADX (14) | 15.79 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture shows bearish sentiment with RSI(14) at 40. The stock trades near the SMA50 of $0.4114 and well below the SMA200 of $1.49, suggesting near-term weakness.
Support is identified at $0.36 and resistance at $0.45, framing the immediate trading range. The 30-day range spans from $0.3147 to $0.4608, highlighting volatility within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.31 | $0.382 | $0.5385 | 0% | Neutral | |
| $0.392 | $0.4912 | $0.6507 | +29% | Bullish | |
| $0.3974 | $0.5123 | $0.7046 | +34% | Bullish | |
| $0.3889 | $0.5131 | $0.7266 | +34% | Bullish | |
| $0.4058 | $0.5465 | $0.7931 | +43% | Bullish | |
| $0.3918 | $0.5375 | $0.7968 | +41% | Bullish | |
| $0.4453 | $0.6216 | $0.9393 | +63% | Bullish | |
| $0.5496 | $0.7797 | $1.20 | +104% | Bullish | |
| $0.5288 | $0.7618 | $1.19 | +99% | Bullish | |
| $0.522 | $0.7633 | $1.21 | +100% | Bullish | |
| $0.696 | $1.09 | $1.83 | +185% | Bullish | |
| $1.05 | $1.83 | $3.38 | +380% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.31 | $0.382 | $0.4664 | +0.42% |
| September 2026 | $0.3481 | $0.4116 | $0.5003 | +7.74% |
| October 2026 | $0.3535 | $0.4208 | $0.5171 | +2.25% |
| November 2026 | $0.3494 | $0.4183 | $0.5185 | -0.60% |
| December 2026 | $0.3583 | $0.4311 | $0.5385 | +3.05% |
Click any year to see its month-by-month IMMP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMMP could reach as high as $0.5385, with a base case around $0.382 and support toward $0.31 — roughly 0% from $0.3804. Price action looks broadly range-bound.
Expect IMMP to range from $0.392 to $0.6507 through 2027. The $0.4912 average target implies a +29% move from current prices. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMMP price prediction for 2028 points to an average of $0.5123 (low $0.3974, high $0.7046) — a potential gain of +34% on today's $0.3804. Momentum favours further upside here.
In 2029, IMMP is projected to trade between $0.3889 and $0.7266, averaging $0.5131 — a potential gain of +34% from today's $0.3804. That is up 0% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Immutep Limited's 2030 outlook centres on $0.5465, within a $0.4058 to $0.7931 range. That is up +7% on the projected 2029 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2031, IMMP could reach as high as $0.7968, with a base case around $0.5375 and support toward $0.3918 — roughly +41% from $0.3804. Buyers look set to stay in control over this stretch.
Expect IMMP to range from $0.4453 to $0.9393 through 2032. The $0.6216 average target implies a +63% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The IMMP price prediction for 2033 points to an average of $0.7797 (low $0.5496, high $1.20) — a potential gain of +104% on today's $0.3804. Buyers look set to stay in control over this stretch.
In 2034, IMMP is projected to trade between $0.5288 and $1.19, averaging $0.7618 — a potential gain of +99% from today's $0.3804. That is -2% versus the projected 2033 average. Momentum favours further upside here.
Immutep Limited's 2035 outlook centres on $0.7633, within a $0.522 to $1.21 range. That is up 0% on the projected 2034 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMMP could reach as high as $1.83, with a base case around $1.09 and support toward $0.696 — roughly +185% from $0.3804. Momentum favours further upside here.
Expect IMMP to range from $1.05 to $3.38 through 2050. The $1.83 average target implies a +380% move from current prices. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMMP today (≈ 2,628.811777 IMMP) could be worth
$4,818.81
+$3,818.81 (+382%) by 2050 · US Dollar
Based on the average projected IMMP price of $1.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMMPwould be worth at today's price.
$1,000 invested in IMMP on Jul 31, 2025 (≈ 574.712641 IMMP) would be worth
$218.62
-$781.38 (-78.1%) today · 0.22× · US Dollar
Based on a IMMP entry price of $1.74 vs. today's $0.3804.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.38 | $1,001.05 | +0.1% |
| 1 month ago | $0.43 | $884.65 | -11.5% |
| 3 months ago | $0.44 | $864.55 | -13.5% |
| 6 months ago | $2.86 | $133.01 | -86.7% |
| 1 year ago | $1.74 | $218.62 | -78.1% |
| All time (5.0y) ago | $3.74 | $101.71 | -89.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMMP forecast.
Our base-case forecast reaches $0.76 around 2033.
Implied market cap at $0.76: $112M
The multi-year forecast paints a bullish arc after 2026. The 2026 average is $0.3808 with a 0% ROI, indicating a neutral stance at that point. By 2027 the average rises to $0.4917 with a 29.1% ROI, and by 2028 to $0.512 with a 34.5% ROI.
The forecast continues higher through 2030 (avg $0.5377, ROI 41.2%), 2031 (avg $0.5248, ROI 37.8%), and 2032 (avg $0.6121, ROI 60.8%). By 2033 the average is $0.7696 and the max $1.20 (ROI 102.1%), with continued bullish momentum into 2034 (avg $0.7471, ROI 96.2%) and 2035 (avg $0.7483, ROI 96.5%).
Looking further out, 2040 shows an avg of $1.06 and a max of $1.82 (ROI 177.8%), and 2050 shows an avg of $1.77 with a max of $3.34 (ROI 363.9%). The sentiment remains bullish across 2030, 2040, and 2050, reflecting a long-term upside potential while acknowledging that these are estimates and not guarantees. Risk factors and market conditions can influence actual outcomes.
Tap a question to reveal the answer.
The 2030 forecast lists a min of $0.3948, an avg of $0.5377, and a max of $0.7905, with a 41.2% ROI and a bullish sentiment.
Forecasts show neutral in 2026 with an average price of $0.3808, then bullish in the following years, with 2027 avg $0.4917 and 2030 avg $0.5377 (ROI 41.2%). The longest-dated outlook shows a potential max of $3.34 in 2050, but these are estimates and not guarantees.
Yes. The 2033 max is $1.20, and the 2035 max is $1.21, indicating the possibility of reaching and exceeding $1.00 in the forecast window.
The 30-day range is $0.3147 to $0.4608.
Immutep Limited Community Discussion
0Share your Immutep Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.